Molpeceres J, Chacón M, Guzmán M, Berges L, del Rosario Aberturas M
Department of Pharmacy and Pharmaceutical Technology, University of Alcalá, Alcalá de Henares, Madrid, Spain.
Int J Pharm. 1999 Sep 30;187(1):101-13. doi: 10.1016/s0378-5173(99)00177-5.
Therapeutic monitoring of Cyclosporine (CyA) by using area under the curve (AUC) from abbreviated kinetic profiles is of recent trend in clinical practice due to the potential improvement in transplant and clinical outcome with costs reduction in mind. Several papers describe successful use of the limited sampling strategy to predict AUCs in different transplant populations when treated with Sandimmun or Sandimmun Neoral. However, the same predictive potential is achieved for the latter formulation with lesser effort. The present paper describes the application of the limited sampling strategies to demonstrate the advantages of using CyA incorporated in polymeric nanoparticles (CyA-NP) as compared to two reference Sandimmun formulations which consisted of an emulsion of the oily solution in milk (SIM-EM) and a microemulsion (SIM-Neoral) formerly tried on rats. Two independent data batches were used: group 1 which included 36, 31 and 10 animals receiving SIM-EM, CyA-NP and SIM-Neoral, respectively, and group 2 made of nine and eight rats treated with SIM-EM and CyA-NP. Several limited sampling equations were derived for each formulation from group 1 by stepwise multiple linear regression. Statistical analysis disclosed that CyA concentrations 8 and 32 h after dose administration vouched for 88 and 69% variability in AUC (0-48 h) for CyA-NP and SIM-EM, respectively. When summed up, these two concentrations revealed nearly 97% of AUC (0-48 h) variability. CyA concentrations 8 h post-treatment with SIM-Neoral explained 89% variability in AUC (0-48 h). This value raised to 98% when a second CyA concentration (24 h) was introduced. The equations derived from group 1 were then employed to predict AUCs in group 2. CyA blood levels at 8 h post-treatment confirmed AUC for CyA-NP (r(2)=0.98) to be very precise and unbiased (error=1. 46%, interval -16.2 to 21.33%), while the results for SIM-EM obtained with the CyA concentration at 32 h were r(2)=0.93 plus error=5.71%, interval -44.33 to 105.94%. Similar results were obtained when the study period was reduced to 24 h. The use of these limited sampling models manifested the coincidence between CyA-NP and SIM-Neoral as well as the advantages of both formulations over SIM-EM when it comes to CyA monitoring.
基于简化动力学曲线下面积(AUC)对环孢素(CyA)进行治疗药物监测是临床实践中的最新趋势,因为这样做在考虑降低成本的同时,有可能改善移植效果和临床结局。几篇论文描述了在使用山地明(Sandimmun)或新山地明(Sandimmun Neoral)治疗时,有限采样策略成功用于预测不同移植人群的AUC。然而,对于后一种制剂,付出较少努力就能实现同样的预测潜力。本文描述了有限采样策略的应用,以证明与两种参比山地明制剂相比,使用载于聚合物纳米粒中的环孢素(CyA-NP)的优势,这两种参比制剂分别是油溶液在乳剂中的乳剂(SIM-EM)和先前在大鼠身上试验过的微乳剂(SIM-Neoral)。使用了两个独立的数据批次:第1组分别包括36只、31只和10只接受SIM-EM、CyA-NP和SIM-Neoral的动物,第2组由9只和8只接受SIM-EM和CyA-NP治疗的大鼠组成。通过逐步多元线性回归从第1组为每种制剂推导了几个有限采样方程。统计分析表明,给药后8小时和32小时的CyA浓度分别解释了CyA-NP和SIM-EM的AUC(0 - 48小时)变异性的88%和69%。将这两个浓度相加,揭示了AUC(0 - 48小时)变异性的近97%。用SIM-Neoral治疗后8小时的CyA浓度解释了AUC(0 - 48小时)变异性的89%。当引入第二个CyA浓度(24小时)时,该值提高到98%。然后使用从第1组推导的方程来预测第2组的AUC。治疗后8小时的CyA血药浓度证实CyA-NP的AUC(r² = 0.98)非常精确且无偏差(误差 = 1.46%,区间 -16.2至21.33%),而在32小时时用CyA浓度获得的SIM-EM的结果为r² = 0.93,误差 = 5.71%,区间 -44.33至105.94%。当研究期缩短至24小时时,获得了类似结果。这些有限采样模型的使用表明了CyA-NP和SIM-Neoral之间的一致性,以及在CyA监测方面这两种制剂相对于SIM-EM的优势。